Related Experiment Videos
Predictive value of phase I studies: relevant criteria
J Sassard1, N Pozet, N Bernard
1Department of Physiology and Clinical Pharmacology, URA CNRS 606, Faculty of Pharmacy, Lyon, France.
Fundamental & Clinical Pharmacology
|January 1, 1990
Summary
Phase I clinical trials reveal drug safety and pharmacokinetics, not efficacy. These studies identify adverse effects and how the body processes new medications, crucial for future drug development.
Area of Science:
- Pharmacology
- Clinical Pharmacology
- Drug Development
Background:
- Phase I studies are the first in-human trials.
- They primarily assess safety and tolerability.
- Therapeutic efficacy prediction is limited in Phase I.
Purpose of the Study:
- To outline the informational value of Phase I studies.
- To detail the predictive value of Phase I for therapeutic effects.
- To describe pharmacodynamic assessments in Phase I.
Main Methods:
- Review of Phase I study objectives and outcomes.
- Analysis of factors influencing therapeutic effect prediction.
- Description of pharmacodynamic endpoints.
Main Results:
- Phase I studies identify undesirable drug effects and their mechanisms.
- Pharmacokinetics and metabolism, including alterations in disease, are elucidated.
- Predictive value for therapeutic effects varies based on drug-target relationship.
Conclusions:
- Phase I studies provide critical safety and pharmacokinetic data.
- They inform about potential adverse events and drug metabolism.
- Pharmacodynamic effects relevant to therapeutic goals can be described in Phase I.